Prestige Biopharma Announces Positive Topline Results from Comparative SAMSON-II Study for HD204, a Potential Biosimilar to Avastin (bevacizumab)
Mar 24, 2026









Shinan District, Qingdao
(+86) 0532-68873099
Monday - Friday 9:00am - 5:00pm